DGAP-News
RedHill Biopharma Ltd.: RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
DGAP-News: RedHill Biopharma Ltd. / Key word(s): Patent
RedHill Biopharma Ltd.: RedHill Biopharma Receives Notice of Allowance of
Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
10.02.2016 / 18:00
The issuer is solely responsible for the content of this announcement.
RedHill Biopharma Ltd.: RedHill Biopharma Receives Notice of Allowance of
Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
10.02.2016 / 18:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release
RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent
Covering RHB-104 Phase III Crohn's Disease Program
- Once granted, the new U.S. patent covering methods of use for RHB-104
is expected to be valid through 2029
- RHB-104 is undergoing a first Phase III study for the treatment of
Crohn's disease in the U.S. and additional countries, with interim
analysis expected during the second half of 2016
- A Phase IIa proof-of-concept study evaluating RHB-104 in patients
treated for relapsing-remitting multiple sclerosis is ongoing, with
top-line interim results expected in the coming weeks
TEL-AVIV, Israel, February 10, 2016 RedHill Biopharma Ltd. (NASDAQ/TASE:
RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company
primarily focused on the development and commercialization of late
clinical-stage, proprietary, orally-administered, small molecule drugs for
inflammatory and gastrointestinal diseases, including cancer, today
announced that it has received a Notice of Allowance from the United States
Patent and Trademark Office (USPTO) for a new patent covering RHB-104.
RHB-104 is a proprietary and potentially groundbreaking antibiotic
combination therapy in oral capsule formulation, with potent intracellular,
anti-mycobacterial and anti-inflammatory properties, currently undergoing a
first Phase III study for Crohn's disease and a Phase IIa study for
multiple sclerosis.
The patent application, entitled "Compositions Comprising Rifabutin,
Clarithromycin, and Clofazamine and Uses Therof" significantly expands
RedHill's patent portfolio covering RHB-104 and is expected to be valid
until 2029 once granted. Upon issuance, RedHill will hold five U.S. patents
and multiple international patents for RHB-104.
Danielle Abramson, Ph.D., RedHill's Director of Intellectual Property &
Research said: "We are very pleased to announce this new addition to
RedHill's already robust patent portfolio covering RHB-104. The Phase III
study with RHB-104 for Crohn's disease, currently ongoing in the U.S. and
additional countries, is advancing well, with interim analysis expected in
Press Release
RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent
Covering RHB-104 Phase III Crohn's Disease Program
- Once granted, the new U.S. patent covering methods of use for RHB-104
is expected to be valid through 2029
- RHB-104 is undergoing a first Phase III study for the treatment of
Crohn's disease in the U.S. and additional countries, with interim
analysis expected during the second half of 2016
- A Phase IIa proof-of-concept study evaluating RHB-104 in patients
treated for relapsing-remitting multiple sclerosis is ongoing, with
top-line interim results expected in the coming weeks
TEL-AVIV, Israel, February 10, 2016 RedHill Biopharma Ltd. (NASDAQ/TASE:
RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company
primarily focused on the development and commercialization of late
clinical-stage, proprietary, orally-administered, small molecule drugs for
inflammatory and gastrointestinal diseases, including cancer, today
announced that it has received a Notice of Allowance from the United States
Patent and Trademark Office (USPTO) for a new patent covering RHB-104.
RHB-104 is a proprietary and potentially groundbreaking antibiotic
combination therapy in oral capsule formulation, with potent intracellular,
anti-mycobacterial and anti-inflammatory properties, currently undergoing a
first Phase III study for Crohn's disease and a Phase IIa study for
multiple sclerosis.
The patent application, entitled "Compositions Comprising Rifabutin,
Clarithromycin, and Clofazamine and Uses Therof" significantly expands
RedHill's patent portfolio covering RHB-104 and is expected to be valid
until 2029 once granted. Upon issuance, RedHill will hold five U.S. patents
and multiple international patents for RHB-104.
Danielle Abramson, Ph.D., RedHill's Director of Intellectual Property &
Research said: "We are very pleased to announce this new addition to
RedHill's already robust patent portfolio covering RHB-104. The Phase III
study with RHB-104 for Crohn's disease, currently ongoing in the U.S. and
additional countries, is advancing well, with interim analysis expected in
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte